vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Broadstone Net Lease, Inc. (BNL). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $118.3M, roughly 1.5× Broadstone Net Lease, Inc.). Broadstone Net Lease, Inc. runs the higher net margin — 28.0% vs 13.3%, a 14.7% gap on every dollar of revenue. On growth, Broadstone Net Lease, Inc. posted the faster year-over-year revenue change (5.5% vs -1.8%). Broadstone Net Lease, Inc. produced more free cash flow last quarter ($269.8M vs $24.6M). Over the past eight quarters, Broadstone Net Lease, Inc.'s revenue compounded faster (6.0% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Broadstone Net Lease, Inc. is a real estate investment trust (REIT) that acquires, owns, and manages a diversified portfolio of single-tenant commercial real estate assets across the United States. Its portfolio covers key segments including industrial facilities, healthcare properties, retail locations, and office spaces, all leased to tenants under long-term net lease agreements.
AMPH vs BNL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $118.3M |
| Net Profit | $24.4M | $33.1M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | — |
| Net Margin | 13.3% | 28.0% |
| Revenue YoY | -1.8% | 5.5% |
| Net Profit YoY | -35.7% | 25.5% |
| EPS (diluted) | $0.51 | $0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $118.3M | ||
| Q3 25 | $191.8M | $114.2M | ||
| Q2 25 | $174.4M | $113.0M | ||
| Q1 25 | $170.5M | $108.7M | ||
| Q4 24 | $186.5M | $112.1M | ||
| Q3 24 | $191.2M | $108.4M | ||
| Q2 24 | $182.4M | $105.9M | ||
| Q1 24 | $171.8M | $105.4M |
| Q4 25 | $24.4M | $33.1M | ||
| Q3 25 | $17.4M | $26.5M | ||
| Q2 25 | $31.0M | $20.2M | ||
| Q1 25 | $25.3M | $16.7M | ||
| Q4 24 | $38.0M | $26.4M | ||
| Q3 24 | $40.4M | $35.6M | ||
| Q2 24 | $37.9M | $35.3M | ||
| Q1 24 | $43.2M | $65.1M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | — | ||
| Q2 25 | 24.2% | — | ||
| Q1 25 | 21.9% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 29.8% | — | ||
| Q2 24 | 30.3% | — | ||
| Q1 24 | 27.9% | — |
| Q4 25 | 13.3% | 28.0% | ||
| Q3 25 | 9.0% | 23.2% | ||
| Q2 25 | 17.8% | 17.8% | ||
| Q1 25 | 14.8% | 15.4% | ||
| Q4 24 | 20.4% | 23.5% | ||
| Q3 24 | 21.1% | 32.8% | ||
| Q2 24 | 20.8% | 33.4% | ||
| Q1 24 | 25.1% | 61.8% |
| Q4 25 | $0.51 | $0.17 | ||
| Q3 25 | $0.37 | $0.14 | ||
| Q2 25 | $0.64 | $0.10 | ||
| Q1 25 | $0.51 | $0.09 | ||
| Q4 24 | $0.74 | $0.13 | ||
| Q3 24 | $0.78 | $0.19 | ||
| Q2 24 | $0.73 | $0.19 | ||
| Q1 24 | $0.81 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $30.5M |
| Total DebtLower is stronger | $608.7M | $2.5B |
| Stockholders' EquityBook value | $788.8M | $2.9B |
| Total Assets | $1.6B | $5.7B |
| Debt / EquityLower = less leverage | 0.77× | 0.87× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $30.5M | ||
| Q3 25 | $276.2M | $82.0M | ||
| Q2 25 | $231.8M | $20.8M | ||
| Q1 25 | $236.9M | $9.6M | ||
| Q4 24 | $221.6M | $14.8M | ||
| Q3 24 | $250.5M | $9.0M | ||
| Q2 24 | $217.8M | $18.3M | ||
| Q1 24 | $289.6M | $221.7M |
| Q4 25 | $608.7M | $2.5B | ||
| Q3 25 | $608.6M | $2.4B | ||
| Q2 25 | $607.7M | $2.1B | ||
| Q1 25 | $603.9M | $2.0B | ||
| Q4 24 | $601.6M | $1.9B | ||
| Q3 24 | $596.4M | $2.0B | ||
| Q2 24 | $586.9M | $1.9B | ||
| Q1 24 | $594.0M | $1.9B |
| Q4 25 | $788.8M | $2.9B | ||
| Q3 25 | $776.7M | $2.9B | ||
| Q2 25 | $757.5M | $2.9B | ||
| Q1 25 | $751.3M | $2.9B | ||
| Q4 24 | $732.3M | $3.0B | ||
| Q3 24 | $727.7M | $3.0B | ||
| Q2 24 | $713.3M | $3.1B | ||
| Q1 24 | $672.4M | $3.1B |
| Q4 25 | $1.6B | $5.7B | ||
| Q3 25 | $1.7B | $5.5B | ||
| Q2 25 | $1.6B | $5.3B | ||
| Q1 25 | $1.6B | $5.2B | ||
| Q4 24 | $1.6B | $5.2B | ||
| Q3 24 | $1.5B | $5.3B | ||
| Q2 24 | $1.5B | $5.3B | ||
| Q1 24 | $1.6B | $5.3B |
| Q4 25 | 0.77× | 0.87× | ||
| Q3 25 | 0.78× | 0.82× | ||
| Q2 25 | 0.80× | 0.73× | ||
| Q1 25 | 0.80× | 0.68× | ||
| Q4 24 | 0.82× | 0.64× | ||
| Q3 24 | 0.82× | 0.65× | ||
| Q2 24 | 0.82× | 0.62× | ||
| Q1 24 | 0.88× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $299.5M |
| Free Cash FlowOCF − Capex | $24.6M | $269.8M |
| FCF MarginFCF / Revenue | 13.4% | 228.1% |
| Capex IntensityCapex / Revenue | 4.5% | 25.1% |
| Cash ConversionOCF / Net Profit | 1.35× | 9.04× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $461.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $299.5M | ||
| Q3 25 | $52.6M | $64.2M | ||
| Q2 25 | $35.6M | $79.3M | ||
| Q1 25 | $35.1M | $71.5M | ||
| Q4 24 | $29.0M | $276.3M | ||
| Q3 24 | $60.0M | $67.3M | ||
| Q2 24 | $69.1M | $74.2M | ||
| Q1 24 | $55.3M | $70.9M |
| Q4 25 | $24.6M | $269.8M | ||
| Q3 25 | $47.2M | $58.0M | ||
| Q2 25 | $25.0M | $76.7M | ||
| Q1 25 | $24.4M | $57.1M | ||
| Q4 24 | $16.6M | $259.5M | ||
| Q3 24 | $46.2M | $60.3M | ||
| Q2 24 | $63.1M | $74.0M | ||
| Q1 24 | $46.5M | $67.7M |
| Q4 25 | 13.4% | 228.1% | ||
| Q3 25 | 24.6% | 50.8% | ||
| Q2 25 | 14.3% | 67.9% | ||
| Q1 25 | 14.3% | 52.5% | ||
| Q4 24 | 8.9% | 231.4% | ||
| Q3 24 | 24.1% | 55.6% | ||
| Q2 24 | 34.6% | 69.9% | ||
| Q1 24 | 27.1% | 64.3% |
| Q4 25 | 4.5% | 25.1% | ||
| Q3 25 | 2.8% | 5.4% | ||
| Q2 25 | 6.1% | 2.3% | ||
| Q1 25 | 6.3% | 13.2% | ||
| Q4 24 | 6.7% | 15.0% | ||
| Q3 24 | 7.2% | 6.5% | ||
| Q2 24 | 3.3% | 0.2% | ||
| Q1 24 | 5.1% | 3.0% |
| Q4 25 | 1.35× | 9.04× | ||
| Q3 25 | 3.03× | 2.43× | ||
| Q2 25 | 1.15× | 3.93× | ||
| Q1 25 | 1.39× | 4.27× | ||
| Q4 24 | 0.76× | 10.47× | ||
| Q3 24 | 1.48× | 1.89× | ||
| Q2 24 | 1.82× | 2.10× | ||
| Q1 24 | 1.28× | 1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
BNL
| Other | $66.9M | 57% |
| Two Thousand Twenty Four Atm Program | $51.4M | 43% |
